Results 191 to 200 of about 438,958 (332)

A study of interferon-.BETA. and interferon-.ALPHA. combination therapy for patients with chronic hepatitis C, high viral load, and genotype Ib: its efficacy for hepatic function.

, 1998
Toshihiko Mizuta, Toshiya Hara, Noriko Fukushima, Ikuko Wada, Iwata Ozaki, Kyosuke Yamamoto   +5 more
openalex   +2 more sources

Comparison of Quantitations of Viral Load in Varicella and Zoster [PDF]

, 2000
Hiroshi Kimura, Shinji Kido, Takao Ozaki, Naoko Tanaka, Yoshinori Ito, Richard K. Williams, Tsuneo Morishima   +6 more
openalex   +1 more source

Nanocarrier‐Based Targeting of Pattern Recognition Receptors as an Innovative Strategy for Enhancing Sepsis Therapy

Advanced Healthcare Materials, EarlyView.
This review highlights recent progress in nanocarriers targeting pattern recognition receptors (PRRs), including Toll‐like and NOD‐like receptors, for enhancing the treatment of bacterial sepsis and related complications. These nanomedicines deliver antibiotics and anti‐inflammatory agents while modulating immune responses.
Eman A. Ismail, Vincent O. Nyandoro, Calvin A. Omolo, Thirumala Govender   +3 more
wiley   +1 more source

Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis. [PDF]

Lancet
Dugdale CM, Ufio O, Giardina J, Shebl F, Coskun E, Pletner E, Torola PR, Cosar D, Shapiro R, Kim M, Mofenson L, Ciaranello AL.   +11 more
europepmc   +1 more source

Course of Viral Load Throughout HIV-1 Infection

, 2000
Caroline Sabin, Helen Devereux, Andrew Phillips, Andrew F. Hill, George Janossy, Christine A. Lee, Clive Loveday   +6 more
openalex   +1 more source

Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA Excision

Advanced Healthcare Materials, EarlyView.
Advancements in ART improve HIV‐1 patient outcomes but are unable to eliminate latent viral DNA. To address this, CXCR4‐targeted lipid nanoparticles (T‐LNPs) for delivering CRISPR‐Cas9 to excise HIV‐1 DNA in infected cells are developed. These T‐LNPs achieve ≈60% HIV‐1 DNA excision efficacy in blood and splenic tissue, demonstrating promise for ...
Sudipta Panja, Lubaba A. Zaman, Chen Zhang, Milankumar Patel, Santhi Gorantla, Prasanta K. Dash, Howard E. Gendelman   +6 more
wiley   +1 more source

CRISPR/Cas9 Reduces Viral Load in a BALB/c Mouse Model of Ocular Herpes Infection. [PDF]

Biomedicines
Garcia LS, de Sousa RMP, Campos VS, Ferreira EM, Cascabulho CM, de Souza EM, de Paula VS.   +6 more
europepmc   +1 more source

Wide Range of Viral Load in Healthy African Green Monkeys Naturally Infected with Simian Immunodeficiency Virus

, 2000
Simoy Goldstein, Ilnour Ourmanov, Charles R. Brown, Brigitte Beer, William R. Elkins, Ronald J. Plishka, Alicia Buckler‐White, Vanessa M. Hirsch   +7 more
openalex   +1 more source

Quantitative and Cost Comparison of Ultrasensitive Human Immunodeficiency Virus Type 1 RNA Viral Load Assays: Bayer bDNA Quantiplex Versions 3.0 and 2.0 and Roche PCR Amplicor Monitor Version 1.5 [PDF]

, 2000
Tarek Elbeik, Edwin D. Charlebois, Patricia Nassos, James O. Kahn, Frederick Hecht, D M Yajko, Valerie L. Ng, Keith Hadley   +7 more
openalex   +1 more source

Molecular Mechanisms of Extracellular Vesicle Biogenesis and Their Impact on the Design of Custom EVs

Advanced Healthcare Materials, EarlyView.
Extracellular vesicles (EVs) are pivotal mediators of intercellular communication and disease, yet the fundamental mechanisms controlling their biogenesis and cargo selection remain unclear. This limitation hinders their diagnostic utility and therapeutic development.
Luís Carvalho Ferraz, Paulo Pereira, João Vasco Ferreira   +2 more
wiley   +1 more source